CO4940458A1 - Novedosos inhibidores de urea n-sustituida de transferasa de proteina farnesilo - Google Patents
Novedosos inhibidores de urea n-sustituida de transferasa de proteina farnesiloInfo
- Publication number
- CO4940458A1 CO4940458A1 CO98034144A CO98034144A CO4940458A1 CO 4940458 A1 CO4940458 A1 CO 4940458A1 CO 98034144 A CO98034144 A CO 98034144A CO 98034144 A CO98034144 A CO 98034144A CO 4940458 A1 CO4940458 A1 CO 4940458A1
- Authority
- CO
- Colombia
- Prior art keywords
- hydrogen
- farnesilo
- alkyl
- protein transferase
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Un compuesto de fórmula (1.0) o una sal o solvatofarmacéuticamente aceptable del mismo, en donde A representa N o N-óxido; X representa N, CH ó C, de manera que cuando X es N ó CH, hay un único enlace al átomo de carbono 11 según se representa por la línea sólida; o cuando X es C, hay un doble enlace al átomo de carbono 11, según se representa por las líneas punteada y sólida; X1 y X2 son independientemente seleccionados entre bromo o cloro, y X3 y X4 son independientemente seleccionados entre hidrógeno, bromo o cloro siempre que por lo menos uno de X3 y X4 sea hidrógeno; Y1 y Y2 son independientemente seleccionados entre hidrógeno o alquilo; Z es =O ó =S; R5 , R6 , R7 y R8 cada uno representa independientemente hidrógeno, -CF3 , -COR10 , alquilo o arilo, y adicionalmente en donde R5 puede combinarse con R6 para representar =O ó =S y/o R7 puede combinarse con R8 para representar =O ó =S; R10 , R19 y R20 representan independientemente hidrógeno, alquilo, alcoxi, arilo, aralquilo, heteroarilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo y heterocicloalquilalquilo, con la condición de que R19 y R20 no sean ambos hidrógeno; V es cero, 1, 2 ó 3 y W es cero ó 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87704997A | 1997-06-17 | 1997-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4940458A1 true CO4940458A1 (es) | 2000-07-24 |
Family
ID=25369144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98034144A CO4940458A1 (es) | 1997-06-17 | 1998-06-16 | Novedosos inhibidores de urea n-sustituida de transferasa de proteina farnesilo |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0989979A1 (es) |
| JP (1) | JP2002506444A (es) |
| KR (1) | KR20010013881A (es) |
| CN (1) | CN1267291A (es) |
| AR (1) | AR013094A1 (es) |
| AU (1) | AU8253598A (es) |
| CA (1) | CA2293706C (es) |
| CO (1) | CO4940458A1 (es) |
| HU (1) | HUP0002954A3 (es) |
| IL (1) | IL133389A0 (es) |
| NZ (1) | NZ501571A (es) |
| PE (1) | PE82799A1 (es) |
| WO (1) | WO1998057948A1 (es) |
| ZA (1) | ZA985205B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| HUP0302913A3 (en) * | 2000-10-05 | 2005-05-30 | Daley George Q Weston | Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same |
| AU2002211427A1 (en) * | 2000-10-05 | 2002-04-15 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| EP1695961A4 (en) * | 2003-12-17 | 2007-10-24 | Takeda Pharmaceutical | UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| TW201524952A (zh) * | 2013-03-15 | 2015-07-01 | Araxes Pharma Llc | Ｋｒａｓ ｇ１２ｃ之共價抑制劑 |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| US10246424B2 (en) | 2015-04-10 | 2019-04-02 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| ES2856880T3 (es) | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3364977A4 (en) | 2015-10-19 | 2019-09-04 | Araxes Pharma LLC | PROCESS FOR SCREENING INHIBITORS OF RAS |
| US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| EP3519402A1 (en) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
| WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| CA3063440A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Covalent inhibitors of kras |
| CN111960990A (zh) * | 2020-07-23 | 2020-11-20 | 宿迁联盛科技股份有限公司 | 一种助剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111235A (en) * | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
| US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| IL117798A (en) * | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
| IL125062A (en) * | 1995-12-22 | 2003-11-23 | Schering Corp | Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases |
| ES2234036T3 (es) * | 1996-09-13 | 2005-06-16 | Schering Corporation | Compuestos utiles para inhibir la farnesil-protein-transferasa. |
| CZ87499A3 (cs) * | 1996-09-13 | 1999-08-11 | Schering Corporation | Substituované deriváty benzocykloheptapyridinu použitelné při léčbě nádorových onemocnění tím, že inhibují farnesylprotein transferázu |
-
1998
- 1998-06-15 EP EP98932717A patent/EP0989979A1/en not_active Withdrawn
- 1998-06-15 PE PE1998000506A patent/PE82799A1/es not_active Application Discontinuation
- 1998-06-15 KR KR1019997011903A patent/KR20010013881A/ko not_active Application Discontinuation
- 1998-06-15 HU HU0002954A patent/HUP0002954A3/hu unknown
- 1998-06-15 CA CA002293706A patent/CA2293706C/en not_active Expired - Fee Related
- 1998-06-15 WO PCT/US1998/011507 patent/WO1998057948A1/en not_active Application Discontinuation
- 1998-06-15 CN CN98808189A patent/CN1267291A/zh active Pending
- 1998-06-15 JP JP50450299A patent/JP2002506444A/ja not_active Ceased
- 1998-06-15 AU AU82535/98A patent/AU8253598A/en not_active Abandoned
- 1998-06-15 IL IL13338998A patent/IL133389A0/xx unknown
- 1998-06-15 ZA ZA985205A patent/ZA985205B/xx unknown
- 1998-06-15 NZ NZ501571A patent/NZ501571A/en unknown
- 1998-06-16 AR ARP980102858A patent/AR013094A1/es unknown
- 1998-06-16 CO CO98034144A patent/CO4940458A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU8253598A (en) | 1999-01-04 |
| IL133389A0 (en) | 2001-04-30 |
| JP2002506444A (ja) | 2002-02-26 |
| WO1998057948A1 (en) | 1998-12-23 |
| CA2293706A1 (en) | 1998-12-23 |
| PE82799A1 (es) | 1999-08-26 |
| HUP0002954A2 (hu) | 2001-06-28 |
| CN1267291A (zh) | 2000-09-20 |
| NZ501571A (en) | 2002-02-01 |
| ZA985205B (en) | 1998-12-15 |
| KR20010013881A (ko) | 2001-02-26 |
| EP0989979A1 (en) | 2000-04-05 |
| AR013094A1 (es) | 2000-12-13 |
| HUP0002954A3 (en) | 2002-11-28 |
| CA2293706C (en) | 2008-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4940458A1 (es) | Novedosos inhibidores de urea n-sustituida de transferasa de proteina farnesilo | |
| TR200100439T2 (tr) | 1H-İmidazopiridin türevleri | |
| TR199802136T2 (xx) | �MPDH enzimi inhibit�rleri olarak �re t�revleri. | |
| CO4970713A1 (es) | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen | |
| NO20044807L (no) | Heratitt C virus inhibitorer | |
| EA200500017A1 (ru) | Новые соединения | |
| ATE226193T1 (de) | Substituierte zyklische amine als metalloproteaseinhibitoren | |
| ES2173683T3 (es) | Inhibidor del radical superoxido. | |
| CY1110399T1 (el) | Ρυθμιστες της τετραϋδροπυρανυλο κυκλοπεντυλο τετραϋδροπυριδοπυριδινης για την ενεργοτητα των υποδοχεων των χημειοκινων | |
| HUP0400579A2 (hu) | Tetralonszármazékok mint tumorellenes gyógyászati hatóanyagok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| DE69420564D1 (de) | Immunsuppressive und antiallergische verbindungen; z.b. n-(3-oxohexanoyl)-homoserinlacton | |
| ATE383861T1 (de) | Vasopressin antagonist und oxytocin antagonist | |
| NO874549D0 (no) | Sulfonperoxycarboxylsyrer, deres anvendelse for blekning og preparater inneholdende samme. | |
| CO5050296A1 (es) | Derivados de 1-arenosulfonil-2-arilo-pirrolidina y de piperidina | |
| NO20000722L (no) | 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater | |
| DK39286A (da) | Imidazolderivater, fremgangsmaade til fremstilling heraf og farmaceutiske praeparater indeholdende disse derivater | |
| NO985335L (no) | 2,4-Diaminopyrimidinderivater | |
| AR012990A1 (es) | Compuestos de benzo(5,6) cicloheptapiridina, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos como inhibidores de laproteina farnesil transferasa. | |
| CO4940475A1 (es) | Novedosos inhibidores de sulfonamida de la farnesil-protein transferasa | |
| DE69728164D1 (de) | Peptidomimetische inhibitoren von der protease des menschlichen cytomegalovirus | |
| AR012730A1 (es) | Compuestos derivados de aminocicloalquilpirrolidina sustituida cis-sustituidos, droga, agente antimicrobiano y compuesto intermediario | |
| ES2038654T3 (es) | Un procedimiento para preparar derivados de tianafteno. | |
| ES2106439T3 (es) | 5-(piperazinilalquil)-1,5-benzotiazepinonas utiles como antagonistas de calcio. | |
| DK1186594T3 (da) | N-alkoxylkyl-N,N-dialkylamin-derivater eller salte deraf og midler mod neurodegenerative sygdomme, som indeholder disse | |
| CO4940478A1 (es) | Derivados de 1-(2-acilimidazol-1-ilalquil) quinuclidino |